Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, University of Tokyo, Tokyo, Japan.
J Gastroenterol. 2012 Apr;47(4):486-8. doi: 10.1007/s00535-012-0530-2. Epub 2012 Feb 11.
We describe a successful living donor liver transplantation (LDLT) using a lymphocytotoxic crossmatch highly positive graft. A 41-year-old woman with alcoholic liver cirrhosis was referred as a potential candidate for LDLT, and her husband was willing to donate his partial liver. As the T-lymphocytotoxic crossmatch titer was over 10,000×, the patient was first infused with rituximab for preoperative desensitization, and then five rounds of plasmapheresis were performed. After the third plasmapheresis, the lymphocytotoxic crossmatch test was negative. A left liver graft including the caudate lobe was implanted, and anti-CD25 antibody (basiliximab) was administered on postoperative days 1 and 4. The postoperative course was uneventful except for an episode of mild acute cellular rejection on postoperative day 27. Although the impact of a lymphocytotoxic crossmatch-positive liver graft on acute cellular rejection and graft survival in LDLT remains controversial, perioperative desensitization may provide benefits when using a highly sensitized liver graft.
我们描述了一例成功的使用淋巴细胞毒交叉配合高度阳性移植物的活体供肝移植(LDLT)。一名 41 岁的女性因酒精性肝硬化被推荐为 LDLT 的潜在候选者,她的丈夫愿意捐献部分肝脏。由于 T 淋巴细胞毒交叉配合滴度超过 10000×,患者首先接受利妥昔单抗进行术前脱敏,然后进行了五轮血浆置换。第三次血浆置换后,淋巴细胞毒交叉配合试验呈阴性。植入了包括尾状叶的左肝移植物,并在术后第 1 天和第 4 天给予抗 CD25 抗体(巴利昔单抗)。术后过程平稳,除了在术后第 27 天出现轻微的急性细胞排斥反应外。尽管淋巴细胞毒交叉配合阳性肝移植物对 LDLT 中的急性细胞排斥反应和移植物存活的影响仍存在争议,但在使用高度致敏肝移植物时,围手术期脱敏可能会带来益处。